| Patched 1-interacting peptide represses fibrosis in pancreatic cancer to augment the effectiveness of immunotherapy Y Oyama, H Onishi, S Koga, M Murahashi, S Ichimiya, K Nakayama, ... Journal of Immunotherapy 43 (4), 121-133, 2020 | 17 | 2020 |
| RBPJ and MAML3: potential therapeutic targets for small cell lung cancer H Onishi, S Ichimiya, K Yanai, M Umebayashi, K Nakamura, A Yamasaki, ... Anticancer research 38 (8), 4543-4547, 2018 | 17 | 2018 |
| PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor A Fujimura, K Nakayama, A Imaizumi, M Kawamoto, Y Oyama, S Ichimiya, ... Cancer Immunology, Immunotherapy 68 (10), 1649-1660, 2019 | 16 | 2019 |
| PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor S Koga, H Onishi, S Masuda, A Fujimura, S Ichimiya, K Nakayama, ... Translational oncology 14 (9), 101152, 2021 | 15 | 2021 |
| Liprin-α4 as a new therapeutic target for sclc as an upstream mediator of hif1α H Onishi, A Yamasaki, K Nakamura, S Ichimiya, K Yanai, M Umebayashi, ... Anticancer research 39 (3), 1179-1184, 2019 | 14 | 2019 |
| GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer S Ichimiya, H Onishi, S Nagao, S Koga, K Sakihama, K Nakayama, ... Oncology reports 45 (3), 997-1010, 2021 | 11 | 2021 |
| FAM115C could be a novel tumor suppressor associated with prolonged survival in pancreatic cancer patients K Saeki, H Onishi, S Koga, S Ichimiya, K Nakayama, Y Oyama, ... Journal of Cancer 11 (8), 2289, 2020 | 10 | 2020 |
| Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with … S Ichimiya, A Fujimura, M Masuda, S Masuda, R Yasumatsu, ... Immunological Investigations, 1-17, 2021 | 7 | 2021 |
| NFκB and TGFβ contribute to the expression of PTPN3 in activated human lymphocytes K Nakayama, H Onishi, A Fujimura, A Imaizumi, M Kawamoto, Y Oyama, ... Cellular Immunology 358, 104237, 2020 | 4 | 2020 |
| C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic conditions S Nagao, H Onishi, M Kawamoto, S Masuda, L Na, S Morisaki, N Iwamoto, ... Journal of Cancer 14 (2), 306-317, 2023 | 3 | 2023 |
| Inactivation of Notch4 attenuated pancreatic tumorigenesis in mice K Saeki, W Qiu, RA Friedman, S Pan, J Lu, S Ichimiya, IIC Chio, ... Cancer Research Communications, 2022 | 2 | 2022 |
| Prediction of negative outcomes in non-surgical treatment for appendiceal abscess in adults Y Sadakari, S Date, S Murakami, S Ichimiya, S Nishimura, H Kawaji, ... Journal of the Anus, Rectum and Colon 2 (2), 59-65, 2018 | 2 | 2018 |
| Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor … S Koga, H Onishi, S Masuda, A Fujimura, S Ichimiya, K Nakayama, ... Translational Oncology 17, 2022 | 1 | 2022 |
| PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor (vol 14, pg … S Koga, H Onishi, S Masuda, A Fujimura, S Ichimiya, K Nakayama, ... TRANSLATIONAL ONCOLOGY 17, 2022 | | 2022 |
| GLI2/Hedgehog Signaling Contributes to the Induction of Malignant Phenotype of Gallbladder Cancer S Ichimiya, H Onishi, S Matsushita, S Koga, Y Fujioka, K Nakayama, ... HPB 23, S347-S348, 2021 | | 2021 |
| Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer A Yamasaki, S Koga, S Ichimiya, K Nakayama, Y Oyama, Y Fujioka, ... Annals of Oncology 30, v808, 2019 | | 2019 |
| Maml3 Contributes to the Induction of Malignant Phenotype for Gallbladder Cancer Via the Morphogenesis Signaling Under Hypoxia L Na, H Onishi, S Ichimiya, Y Yamada, S Masuda, S Nagao, S Koga, ... Available at SSRN 4220679, 0 | | |
